CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced it will present at the Morgan Stanley 23rd Annual Global Health Care Conference on Monday, September 8, 2025, at 7:45 a.m. EDT.
The presentation will be webcast live, with a replay available afterward through the company’s investor relations site.
Madrigal specializes in treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. Its lead therapy, Rezdiffra (resmetirom), is the first FDA- and European Commission-approved medication for MASH with moderate to advanced fibrosis. The company is also conducting a Phase 3 trial evaluating the drug in patients with compensated MASH cirrhosis.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.